Radiation-induced apoptosis: Predictive and therapeutic significance in radiotherapy of prostate cancer (Review)

Oncology Reports

Volumn 7, Issue 4, 2000, Pages 699-706

  Szostak, Michael J ^a   Kyprianou, Natasha ^a,b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; bcl 2; Prostate cancer; Radiation

Indexed keywords

APOPTOSIS; BLOOD; BONE TUMOR; HUMAN; MALE; METASTASIS; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; PROSTATECTOMY; RADIATION EXPOSURE; REVIEW;

APOPTOSIS; BONE NEOPLASMS; HUMANS; MALE; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0034220882     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.4.699     Document Type: Review

References (94)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 49: 8-31, 1999.
2. Schellhammer PF: Radiation therapy for localized prostate cancer: what has been and still remains to be learned. In: Monographs in Urology. Stamey T (ed). Stanford, CA, Medical Directions Publishing 15: pp78-92, 1994.
3. Roach M III: Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Eur J Urol 32 (Suppl 3): 48-54, 1997.
4. Schellhammer PF and El-Mahdi AM: Local failure and related complications after definitive treatment of carcinoma of the prostate by irradiation or surgery. Urol Clin N Amer 17: 835-851, 1990.
5. Scherr DS, Vaughan ED Jr, Wei J, Chung M, Felsen D, Allbright R and Knudsen BS: Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 162: 12-17, 1999.
6. Scardino PT and Wheeler TM: Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr 7: 95-103, 1988.
7. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojnok J, Oesterling JE, Scardino PT and Pearson JD: Combination of prostate specific antigen, clinical stage and gleason score to predict pathologic stage of localized prostate cancer in a multi-institutional update. JAMA 277: 1445-1451, 1997.
8. Lerner SE, Blute ML and Zincke H: Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 14 (Suppl): 12-21, 1996.
9. Pettaway CA: Prognostic markers in clinically localized prostate cancer. Tech Urol 4: 35-42, 1998.
10. Hall EJ: Radiobiology for the Radiologist. 4th edition. JB Lippincott Co., Philadelphia, 1994.
11. Withers HR: Radiation biology and treatment options in radiation oncology. Cancer Res 59 (Suppl): 1676s-1684s, 1999.
12. Ling CC, Guo M, Chen CH and Deloherey T: Radiation induced apoptosis: effects of cell age and dose fractionation. Cancer Res 55: 5207-5212, 1995.
13. Rupnow BA, Murtha AD, Alarcon RM, Giaccia AJ and Knox SJ: Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res 58: 1779-1784, 1998.
14. Ennis RE and Peschel RE: Radiation therapy for prostate cancer long-term results and implications for future advances. Cancer 72: 2644-2650, 1993.
15. Ameisen JC: The origin of programmed cell death. Science 272: 1278-1279, 1996.
16. Kiess W and Gallaher B: Hormonal control of programmed cell death/apoptosis (Review). Soc Eur J Endocrinol 138: 482-491, 1998.
17. Oltvai, ZN and Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes. Cell 79: 189-192, 1994.
18. Kyprianou N, Bains A and Rhee JG: Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of prostate cancer cells. Prostate 32: 266-271, 1997.
19. Jaattela M: Escaping cell death: survival proteins in cancer (Review). Exp Cell Res 248: 30-43, 1999.
20. Kyprianou N and Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552-562, 1988.
21. Isaacs JT, Furuya Y and Berges R: The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 5: 391-400, 1994.
22. Kyprianou N: Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J Ural 12: 299-303, 1994.
23. Sklar GN, Eddy HA, Jacobs SC and Kyprianou N: Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J Urol 150: 1526-1532, 1994.
24. Palayoor ST, Bump EA, Teicher BA and Coleman CN: Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin. Radiat Res 148: 105-114, 1997.
25. Algan O, Stobbe CC, Helt AM, Hanks GE and Chapman JD: Radiation inactivation of human prostate cells: the role of apoptosis. Radiat Res 146: 267-275, 1996.
26. Huang A, Candour-Edwards R, Rosenthal SA, Siders DB, Deitch AD and Devere White RW: p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 51: 346-351, 1998.
27. Grossfeld GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V, Waldman FM and Carroll PR: Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol 159: 1437-1443, 1998.
28. Yin CY, Knudson CM, Korsmeyer SJ and Van Dyke T: Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637-640, 1997.
29. Levine AJ, Momand J and Finlay CA: The p53 tumor suppressor gene. Nature 351: 453-456, 1991.
30. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 879-886, 1992.
31. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
32. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
33. Gartel, AL, Serfas MS and Tyner AL: p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213: 138-149, 1996.
34. Sarkar FH, Li Y, Sakr WA, Grignon DJ, Madan SS, Wood DP Jr and Adsay V: Relationship of p21 (WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (Pca). Prostate 40: 256-260, 1999.
35. Brown JM and Wouters BG: Apoptosis, p53 and tumor cell sensitivity to anticancer agents (Review). Cancer Res 59: 1391-1399, 1999.
36. Ding HF and Fisher DE: Mechanisms of p53-mediated apoptosis. Crit Rev Oncol 9: 83-98, 1998.
37. Korsmeyer SJ: bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
38. Tsujimoto Y, Finger LR, Yunis J, Nowell PC and Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14:18) chromosome translocation. Science 226: 1097-1099, 1984.
39. Hockenberry DM, Zutter M, Hickey N, Nahm M and Kormeyer SJ: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991.
40. Green DR and Reed JC: Mitochondria and apoptosis (Review). Science 281: 1309-1316, 1998.
41. Korsmeyer SJ: Bcl-2 gene family and the regulation of programmed cell death. Cancer Res 59 (Suppl): 1693s-1700s, 1999.
42. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE and Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4: 327-332, 1993.
43. Knudson MC and Korsmeyer SJ: Bcl-2 and bax function independently to regulate cell death. Nat Genet 16: 358-363, 1997.
44. Cheng EH, Levine B, Boise LH, Thompson CB and Hardwick JM: Bax-independent inhibition of apoptosis by bcl-xL. Nature 379: 554-556, 1996.
45. McDonnell TS, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM and Campbell ML: Expression of the protoncogene bcl-2 in the human prostate and its association with emergence of androgen independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
46. Tu H, Jacobs SC, Borkowski A and Kyprianou N: Significance of apoptosis in prostate cancer progression: relationship with cell proliferation, TGF-B and BCL-2 expression. Int J Cancer 69: 357, 1996.
47. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
48. Gallo O, Boddi V, Calzolari A, Simonetti L, Trovati M and Bianchi S: bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin Cancer Res 2: 261-267, 1996.
49. Fontanini G, Vignati S, Mussi A, Lucchi M, Angeletti CA, Basolo F and Bevilacqua G: Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small cell lung cancer. Br J Cancer 71: 1003-1007, 1995.
50. Tron, VA, Krajewski S, Klein-Parker G, Li G, Ho VC and Reed JC: Immunohistochemical analysis of bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 146: 643-650, 1995.
51. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, DiFronzo G, Rilke F and Veronesi U: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
52. Hague A, Moorghen M, Hicks D, Chapman M and Paraskeva C: Bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene 9: 3367-3370, 1994.
53. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC: Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576, 1996.
54. Datta R, Manome Y, Taneja N, Boise LH, Weichselbaum R, Thompson CB, Slapak CA and Kufe D: Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ 6: 363-370, 1995.
55. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC and Mihatsch MJ: Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol 148: 1557-1565, 1996.
56. Kyprianou N, King ED, Bradbury D and Rhee JG: bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70: 341-348, 1997.
57. Gross A, Jockel J, Wei MC and Korsmeyer SJ: Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 17: 3878-3885, 1998.
58. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homologue, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
59. Zhan, Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM and Fornace AJ Jr: Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9: 3743-3751, 1994.
60. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi ZG and Youle RG: Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139: 1287-1292, 1997.
61. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S and Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471-4478, 1995.
62. Mackey TJ, Borkowski A, Amin P, Jacobs SJ and Kyprianou N: bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52: 1085-1090, 1998.
63. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA and Yuan J: Caspase-12 mediates endoplasmic reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403: 98-103, 2000.
64. Newman R, Kramer A, Borkowski A, Jacobs SC and Kyprianou N: Loss of caspase-1 protein expression in human prostate cancer. Int J Cancer (In press).
65. Zou H, Li Y, Liu X and Wang X: An Apaf-1, cytochrome c multimeric complex is a functional apoptosome that activates pro-caspase-9. J Biol Chem 274: 11549-11556, 1999.
66. Eiseman JL, Rogers FA, Guo Y, Kauffman J, Sentz DL, Klinger MF, Callery PS and Kyprianou N: Tumor targeted apoptosis by a novel spermine analogue, 1,12-Diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer. Cancer Res 58: 4864-4870, 1998.
67. Marton LJ and Pegg AE: Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol 35: 55-91, 1995.
68. Peehl D, Wong S and Stamey T: Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors. J Urol 145: 624-630, 1991.
69. Vignon F, Prebois C and Rochefort H: Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 84: 38-42, 1991.
70. Stein CA, LaRocca RV, Thomas R, McAtee N and Meyers CE: Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499-508, 1989.
71. Garcia-Schurmann JM, Schulze H, Haupt G, Pastor J, Allolio B and Senge T: Suramin treatment in hormone- and chemotherapy-refractory prostate cancer. Urology 53: 535-541, 1999.
72. Garzoto M, White JM, Jiang Y, Ehleiter D, Liao WC, Haimovitz FA, Fuks Z and Kolesnick R: 12-O-tetradecanoyl-phorbol-13-acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase. Cancer Res 58: 2260-2266, 1998.
73. Kimura K, Bowen C, Spiegel S and Gelmann EP: Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res 59: 1606-1614, 1999.
74. Schwartz JE, Scuderi P, Wiggins C, Rudolph A and Hersh EM: A phase 1 trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. Biotherapy 1: 207-214, 1989.
75. Joon DL, Hasegawa M, Sikes C, Khoo VS, Terry NH, Zagars GK, Meistrich ML and Pollack A: Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38: 1071-1077, 1997.
76. Pilepich MV, Krall JM, Sause WT, Johnson RJ, Russ HH, Hanks GE, Perez CA, Zinninger M and Martz KL: Prognostic factors in carcinoma of the prostate-analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 13: 339-349, 1987.
77. Crook JM, Perry GA, Robertson S and Esche BA: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 45: 624-631, 1995.
78. Forman JD, Dumar R, Haas G, Montie J, Porter AT and Mesina CF: Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 13: 8-15, 1995.
79. Pilepich MV, Krall JM, Al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616-623, 1995.
80. Laverdiere J, Gomez JL, Cusan L, et al: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 247-252, 1997.
81. Spry NA, Meffan PM, Christie DR and Morum PE: Orchidectomy prior to definitive radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 34: 1045-1053, 1996.
82. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU and Grignon D: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15: 1013-1021, 1997.
83. Pollack A, Zagars GK and Kopplin S: Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys 32: 13-20, 1995.
84. American Society for Therapeutic Radiation and Oncology Consensus Panel: Consensus Statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1035-1041, 1997.
85. Zagars GK, Pollack A, Kavadi VS and Eschenbach AC: PSA and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32: 293-306, 1995.
86. Critz FA, Levinson K, Williams WH, Holladay D, Holladay C and Griffin V: Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer. Urology 49: 668-672, 1997.
87. Zietman AL, Coen JJ, Shipley WU, Willet CG and Efird JT: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151: 640-645, 1994.
88. Davis JW, Kolm P, Wright GL, Kuban D, El-Mahdi A and Schellhammer P: The durability of external beam radiation therapy for prostate cancer: can it be identified? J Urol 162: 758-761, 1999.
89. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ and Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-874, 1998.
90. Lee JM and Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90: 5742-5746, 1993.
91. Stattin P, Damber JE, Modig H and Bergh A: Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients. Int J Radiat Oncol Biol Phys 35: 885-889, 1996.
92. Kyprianou N and Rock S: Radiation-induced apoptosis of human prostate cancer cells is independent of mutant p53 overexpression. Anticancer Res 18: 897-905, 1998.
93. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU and Cox JD: p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 89: 158-165, 1997.
94. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE and Oltvai XN: Bcl-2/bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4: 327-332, 1993.